Overview

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

Status:
Active, not recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

This is an open label, multi-institutional, single arm study of a phase Ib study, followed by a phase II study of durvalumab with radiation therapy (RT) in patients with urothelial cancer (UC). No randomization or blinding is involved.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Monika Joshi
Monika Joshi, MD

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Durvalumab